Clinical impact evaluation of multiplex PCR test for joint infection

Clinical impact evaluation of multiplex PCR joint infection panel

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1052260006

Enrollment

900

Registered

2026-04-06

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint infection Joint infection, septic arthritis

Interventions

Addition of multiplex PCR joint infection panel

Multiplex Polymerase Chain Reaction

joint infection panel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with suspected joint infection for which joint fluid or synovial fluid has been obtained with gram stain and culture.

Exclusion criteria

Exclusion criteria: Lack of residual synovial fluid (0.2ml) to run multipmex PCR test

Design outcomes

Primary

Measure	Time frame
antimicrobial use (days of therapy, type), hospitalization rate, length of stay	—

Secondary

Measure	Time frame
cost, recurrent joint infection, long-term antimicrobial use, time to appropriate antimicrobial treatment	—

Contacts

Public ContactTaito Kitano

Nara Prefecture General Medical Center, Nara Medical University Hospital

taito.kitano0110@gmail.com+81-744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026